Cargando…

Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity

Nonalcoholic fatty liver disease in human obesity is characterized by the multifactorial nature of the underlying pathogenic mechanisms, which include misregulation of PPARs signaling. Liver PPAR-α downregulation with parallel PPAR-γ and SREBP-1c up-regulation may trigger major metabolic disturbance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Videla, Luis A., Pettinelli, Paulina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526338/ https://www.ncbi.nlm.nih.gov/pubmed/23304111 http://dx.doi.org/10.1155/2012/107434

Ejemplares similares

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease
por: Alegre, Nadia Soledad, et al.
Publicado: (2020)

Dietary and Nutritional Interventions in Nonalcoholic Fatty Liver Disease in Pediatrics
por: Farías, Camila, et al.
Publicado: (2023)

Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View
por: Valenzuela, Rodrigo, et al.
Publicado: (2020)

Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
por: Zarghamravanbakhsh, Paria, et al.
Publicado: (2021)

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
por: Chen, Changxi, et al.
Publicado: (2022)

Transcriptional regulation and its misregulation in Alzheimer’s disease
por: Chen, Xiao-Fen, et al.
Publicado: (2013)

Transcriptional Regulation and Its Misregulation in Human Diseases
por: Casamassimi, Amelia, et al.
Publicado: (2023)

Limited expression of toll-like receptor 9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease
por: Yu, Jung Hwan
Publicado: (2020)

Obesity and nonalcoholic fatty liver disease: current perspectives
por: Sarwar, Raiya, et al.
Publicado: (2018)

Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway
por: Huang, Ping, et al.
Publicado: (2022)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Comparison between obese and non-obese nonalcoholic fatty liver disease
por: Chan, Wah-Kheong
Publicado: (2023)

The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity
por: Pacifico, Lucia, et al.
Publicado: (2016)

Misregulation of the proline rich homeodomain (PRH/HHEX) protein in cancer cells and its consequences for tumour growth and invasion
por: Gaston, Kevin, et al.
Publicado: (2016)

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease
por: Wang, Yun-liang, et al.
Publicado: (2015)

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
por: Lee, Yong-Jik, et al.
Publicado: (2017)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease in obese and nonobese pediatric patients
por: Kim, Eun Jeong, et al.
Publicado: (2019)

Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
por: El Ouaamari, Abdelfattah, et al.
Publicado: (2013)

Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease
por: Chen, Wei, et al.
Publicado: (2018)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
por: Kamata, Shotaro, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
por: Masuoka, Howard C, et al.
Publicado: (2013)

Surgical treatment of nonalcoholic fatty liver disease in severely obese patients
por: Vander Naalt, Steven J, et al.
Publicado: (2014)

Gut Microbiota and Clinical Disease: Obesity and Nonalcoholic Fatty Liver Disease
por: Park, Ji Sook, et al.
Publicado: (2013)

Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer
por: Divella, Rosa, et al.
Publicado: (2019)

Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review
por: Hashem, Anas, et al.
Publicado: (2021)

Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
por: Qadri, Sami, et al.
Publicado: (2021)

Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease
por: Ristic-Medic, Danijela, et al.
Publicado: (2022)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis
por: Kang, Seong Hee, et al.
Publicado: (2023)

Expression of STING in Women with Morbid Obesity and Nonalcoholic Fatty Liver Disease
por: Bertran, Laia, et al.
Publicado: (2023)

Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy
por: Huang, Chi-Ren, et al.
Publicado: (2021)

Impact of Weight Reduction on Thyroid Function and Nonalcoholic Fatty Liver among Egyptian Adolescents with Obesity
por: Amin, Mona Karem, et al.
Publicado: (2022)

Misregulated Posttranscriptional Checkpoints: Inflammation and Tumorigenesis
por: Brewer, Gary
Publicado: (2001)

Misregulation of the IgH Locus in Thymocytes
por: Kumari, Gita, et al.
Publicado: (2018)

Impact of obesity on liver function tests: is nonalcoholic fatty liver disease the only player? A review article
por: El-Eshmawy, Mervat M.
Publicado: (2023)

The Role of Olfactomedin 2 in the Adipose Tissue–Liver Axis and Its Implication in Obesity-Associated Nonalcoholic Fatty Liver Disease
por: Barrientos-Riosalido, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cvuuj46tutclvgskf3bp1rpoog